{"id":"W3113132520","doi":"10.1016/j.annonc.2020.12.004","title":"Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Oncology; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088155,0.0002344342,0.0009464648,0.00003887872,0.00005975464,0.00001151088,0.0004773753,0.0002511246,0.00004115237],"category_scores_gemma":[0.001009026,0.0001696605,0.0001906933,0.0001920637,0.0002166057,0.000006118766,0.0002751486,0.000210483,0.00002228383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001516951,"about_ca_system_score_gemma":0.0004384088,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006123176,"about_ca_topic_score_gemma":0.0002446538,"domain_scores_codex":[0.9971924,0.0009054325,0.0008582078,0.0005423919,0.0001755137,0.0003260198],"domain_scores_gemma":[0.9984177,0.0004279292,0.0003905765,0.000483238,0.0001526867,0.000127821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6678056,0.002795838,0.001069976,0.00002962055,0.001039265,0.0003254377,0.007007802,0.0001063028,0.2352479,0.0001696565,0.0597681,0.02463454],"study_design_scores_gemma":[0.7094726,0.01865496,0.002738677,0.00002967246,0.0002239812,0.00001811997,0.001435091,0.0002189094,0.07215981,0.0002164266,0.1942652,0.0005665947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850333,0.001420817,0.00005139605,0.004605439,0.0002490288,0.001115144,0.000139744,0.00001534273,0.007369834],"genre_scores_gemma":[0.9939355,0.0004728301,0.0001255146,0.004383102,0.0003973314,0.0000505723,0.0004899736,0.00002255264,0.0001226075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1630881,"threshold_uncertainty_score":0.6918554,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06816358705992281,"score_gpt":0.3451095596220558,"score_spread":0.276945972562133,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}